Literature DB >> 3871172

Lysis of spontaneous murine breast tumors by human interleukin 2-stimulated syngeneic T-lymphocytes.

V J Merluzzi, D M Savage, L Souza, T Boone, R Mertelsmann, K Welte, K Last-Barney.   

Abstract

In vitro and in vivo cytotoxic assay systems show that primary explants of spontaneous mammary tumors from CD8F1 mice are susceptible to lysis by interleukin 2-stimulated, syngeneic T-lymphocytes.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3871172

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  3 in total

1.  In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2).

Authors:  N Saijo; A Ozaki; H Nakano; M Sakurai; H Takahashi; Y Sasaki; A Hoshi
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Lysis of fresh murine mammary tumor cells by syngeneic natural killer cells and lymphokine-activated killer cells.

Authors:  I H Ames; C E Gates; A M Garcia; P A John; A K Hennig; R H Tomar
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.

Authors:  T Sano; N Saijo; Y Sasaki; T Shinkai; K Eguchi; T Tamura; M Sakurai; H Takahashi; H Nakano; K Nakagawa
Journal:  Jpn J Cancer Res       Date:  1988-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.